Mira Hellmann, MD, discusses how the use of PARP inhibitors as treatment of patients with gynecologic cancers has evolved since they were first introduced into the treatment landscape up to studies evaluating these therapies today in a variety of patient populations, particularly in patients with ovarian cancer.
Mira Hellmann, MD a gynecologic oncologist at John Theurer Cancer Center, Hackensack University Medical Center, discusses how the use of PARP inhibitors as treatment of patients with gynecologic cancers has evolved since they were first introduced into the treatment landscape up to studies evaluating these therapies today in a variety of patient populations, particularly in patients with ovarian cancer.
PARP inhibitors have shown significant improvement in disease status, Hellman says, and they have created a whole world of treatments and disease management, Hellmann says. It was thought that PARP inhibition was limited to patients withBRCA1/2mutations, but more data have demonstrated efficacy in patients who do not harbor these mutations.
Hellmann says that research has shown that PARP inhibitors are efficacious in patients who are homologous recombination deficiency (HRD)-positive, while other studies have shown that those who are not HRD-positive or have theBRCA1/2mutations still receive benefit from the PARP inhibitors. A number of presentations at recent meetings have demonstrated benefit from PARP inhibitors, Hellman concludes.
<< View more resources and information regarding gynecologic cancers
Targeted Therapies Continue to Push the Field of EGFRm Lung Cancer Forward
December 6th 2023In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.
Read More
Holloway Discusses the Rationale for PARP Inhibition in Advanced Ovarian Cancer
November 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Holloway, MD, explored the state of PARP inhibitors for patients with advanced ovarian cancer including the PRIMA trial of niraparib.
Read More